Managing MEK Inhibitor Adverse Effects and Safety in NF1-PN

In this segment, the physicians focus on the adverse-effect profiles and safety considerations associated with MEK inhibitor therapy for neurofibramatosis type 1 plexiform neurofibromas (NF1-PN). They note that selumetinib and mirdametinib generally share similar adverse effects, and that effective management—particularly of skin and gastrointestinal symptoms—largely determines tolerability. One physician explains that proactive counseling, including guidance on bleach baths, emollients, and early use of doxycycline in adolescents, has significantly reduced the severity of skin reactions. They emphasize that gastrointestinal symptoms can be minimized through parental involvement with younger children and careful dietary adjustments, including avoidance of lactose, gluten when needed, and greasy fast foods.

The discussion also covers rare but more serious toxicities, such as left ventricular dysfunction, which is monitored through baseline and periodic echocardiograms. Ophthalmologic complications are addressed as well, with updated guidance allowing less frequent eye exams in children during the first year of therapy. Overall, both physicians emphasize monitoring and proactive management greatly improve treatment adherence and safety.